Kiniksa reported third quarter revenue of $286 million driven by sales of ARCALYST, an IL-1 modulator for recurrent pericarditis, significantly up from the prior year. The company raised its full-year sales guidance to $1.045-$1.05 billion.
Kiniksa reported third quarter revenue of $286 million driven by sales of ARCALYST, an IL-1 modulator for recurrent pericarditis, significantly up from the prior year. The company raised its full-year sales guidance to $1.045-$1.05 billion.